DOCSLIB.ORG

ADHD, Keywords: Pharmacological Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
ADHD, Keywords: Pharmacological Treatment BMJ Confidential: For Review Only Methylph enidate for attention deficit hyperactivity disorder in children and adolescents. A Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials Journal: BMJ Manuscript ID: BMJ.2015.027217 Article Type: Research BMJ Journal: BMJ Date Submitted by the Author: 28-May-2015 Complete List of Authors: Storebø, Ole Jakob; Psychiatric Research Unit, Psychiatric Department Krogh, Helle; Psychiatric Research Unit, Psychiatric Department Ramstad, Erica Linda; Psychiatric Research Unit, Psychiatric Department Maia, Carlos; Federal University of Rio, Holmskov, Mathilde; Psychiatric Research Unit, Psychiatric Department Skoog, Maria; Copenhagen Trial Unit, Centre for Clinical Intervention Research Nilausen, Trine; Psychiatric Research Unit, Psychiatric Department Magnusson, Frederik; Psychiatric Research Unit, Psychiatric Department Zwi, Morris; Islington CAMHS, Whittington Health Gillies, Donna; Western Sydney Local Health District, Mental Health Rosendal, Susanne; Psychiatric Centre North Zealand, Groth, Camilla; Pediatric Department,, Herlev University Hospital Rasmussen, Kirsten; Psychiatric Research Unit, Psychiatric Department Gauci, Dorothy; Department of Health Information and Research, Kirubakaran, Richard; South Asian Cochrane Network & Center, Prof. BV Moses Center for Evidence-Informed Health Care and Health Policy Forsbøl, Bente; Child Psychiatric Clinic, Child and Adolescent Psychiatric Department Simonsen, Erik; Psychiatric Research Unit, Psychiatric Department Gluud, Christian; Rigshospitalet, Copenhagen University Hospital, The Copenhagen Trial Unit, Centre for Clinical Intervention Research Attention Deficit Hyperactivity Disorder, Methylpheniate , Ritalin, ADHD, Keywords: Pharmacological treatment https://mc.manuscriptcentral.com/bmj Page 1 of 615 BMJ 1 2 3 4 5 6 7 8 Confidential: For Review Only 9 10 Methylphenidate for attention deficit hyperactivity disorder in 11 12 children and adolescents. A Cochrane systematic review with meta- 13 14 15 analyses and trial sequential analyses of randomised clinical trials* 16 17 18 19 Ole Jakob Storebø senior researcher1,2,4 , Helle B. Krogh medical student 1,2 , Erica Ramstad medical 20 21 student 1,2 . Carlos R Moreira Maia psychiatrist 5, Mathilde Holmskov medical student 1, Maria Skoog 22 23 research fellow 3, Trine Danvad Nilausen physician 1, Frederik L. Magnusson medical student 1, 24 6 25 Morris Zwi, child & adolescent psychiatrist and clinical director , Donna Gillies, senior 26 7 8 9 27 researcher , Susanne Rosendal, psychiatrist , Camilla Groth Ph.D. student , Kirsten Buch 28 1 10 11 29 Rasmussen, librarian , Dorothy Gauci, physican , Richard Kirubakaran physican , Bente Forsbøl, 30 child and adolescent psychiatrist 2, Erik Simonsen, professor and head of department 1,12 , Christian 31 32 Gluud, head of department 3,13 33 34 35 36 1Psychiatric Research Unit, Region Zealand Psychiatry, Roskilde, Denmark; 2Child and Adolescent 37 38 Psychiatric Department, Region Zealand, Denmark; 3Copenhagen Trial Unit, Centre for Clinical 39 40 Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; 41 4 42 Psychological Institute, Faculty of Health Science, South Danish University, Odense, Denmark ; 43 5 6 44 Federal University of Rio Grande do Sul, Porto Alegre, Brazil; Islington CAMHS, Whittington 45 7 46 Health, UK; Western Sydney Local Health District; Mental Health, Parramatta, Australia; 47 8Psychiatric Centre North Zealand, The Capital Region of Denmark, Denmark; 9Pediatric 48 49 Department, Herlev University Hospital, Herlev, Denmark; 10 Department of Health Information and 50 51 52 53 54 55 56 1 57 58 59 60 https://mc.manuscriptcentral.com/bmj BMJ Page 2 of 615 1 2 3 4 5 6 7 8 Research,Confidential: G’Mangia, Malta; 11 South Asian Cochrane Network For & Center, Prof.Review BV Moses Center Only 9 10 for Evidence-Informed Health Care and Health Policy, Christian Medical College, Vellore, India; 11 12 12 Institute of Clinical Medicine, Faculty of Health and Medical Sciences, Copenhagen University, 13 13 14 Copenhagen, Denmark; The Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for 15 16 Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, 17 Copenhagen, Denmark. 18 19 20 21 Erica Ramstad and Helle B. Krogh are co-second authors on this review. 22 23 24 25 26 27 * This article is based on a Cochrane Review published in the Cochrane Database of Systematic 28 29 Reviews (CDSR) YYYY, Issue X, DOI: 10.1002/14651858.CD00xxxx 30 31 (see www.thecochranelibrary.com for information). Cochrane Reviews are regularly updated as 32 33 new evidence emerges and in response to feedback, and the CDSR should be consulted for the most 34 recent version of the review. 35 36 37 38 39 40 41 42 Correspondence to: Ole Jakob Storebø, Psychiatric Research Unit, Psychiatric Department, Region 43 44 Zealand, Denmark. [email protected] . Phone nr: +45 25 11 99 01 Field Code Changed 45 46 47 48 49 50 51 52 53 54 55 56 2 57 58 59 60 https://mc.manuscriptcentral.com/bmj Page 3 of 615 BMJ 1 2 3 4 5 6 7 8 Confidential: For Review Only 9 10 Abstract 11 12 Objective To assess the benefits and harms of methylphenidate in children and adolescents with 13 14 attention deficit hyperactivity disorder (ADHD). 15 16 17 Design Systematic review of randomised clinical trials with meta-analyses and trial sequential 18 19 analyses. 20 21 22 Data sources We searched CENTRAL, Ovid MEDLINE, EMBASE, CINAHL, PsycINFO, ISI 23 Conference Proceedings Citation Index, WHO's trials registry portal (ICTRP) and 'Clinical Trials 24 25 registry´ up to March 2015. We also screened reference lists of identified reviews, meta-analyses 26 27 and a selection of included trials for additional relevant articles. Furthermore, we contacted 28 29 pharmaceutical companies manufacturing methylphenidate for additional published as well as 30 31 unpublished data. 32 33 34 Review methods Using The Cochrane Collaboration methodology, we reviewed randomised 35 36 clinical trials comparing methylphenidate versus placebo or no intervention. Outcomes assessed 37 38 were ADHD symptoms, serious adverse events, non-serious adverse events, general behaviour and 39 40 quality of life. Meta-analyses and trial sequential analyses were conducted. We used the Grading of 41 Recommendations Assessment, Development and Evaluation to assess quality. 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 3 57 58 59 60 https://mc.manuscriptcentral.com/bmj BMJ Page 4 of 615 1 2 3 4 5 6 7 8 Confidential: For Review Only 9 10 11 Results We included 185 randomised clinical trials, 38 parallel (5111 participants) and 147 cross- 12 13 over trials (7134 participants). The quality of evidence was very low for efficacy outcomes and low 14 15 for safety outcomes. We found small benefits for methylphenidate on ADHD symptoms (SMD - 16 17 0.77, 95% CI -0.90 to -0.64, 19 trials, 1698 participants) corresponding to an average change of 9.6 18 points on the ADHD rating scale, 3 points over the minimal clinical relevant difference of 6.6., 19 20 general behaviour (SMD -0.87, 95% CI -1.04 to -0.71, 5 trials, 668 participants) and quality of life 21 22 (SMD 0.61, 95% CI 0.42 to 0.80, 3 trials, 514 participants). Methylphenidate does not appear to 23 24 increase the risk of serious adverse events (relative risk (RR) 0.98, 95% CI 0.44 to 2.22, 9 trials, 25 26 1532 participants) but increases the risk of non-serious adverse events overall (RR 1.29, 95% CI 27 28 1.10 to 1.51, 21 trials, 3132 participants) as well as several specific adverse events. 29 30 Conclusion Methylphenidate appears to have a small beneficial effect on ADHD symptoms, 31 32 general behaviour and quality of life, seems without an increased risk of serious adverse events, but 33 34 it is associated with a relatively high risk of non-serious adverse events overall. Due to lack of 35 36 blinding, outcome reporting bias, vested interests, and heterogeneity, the quality of the evidence is 37 38 very low to low for all outcomes. Accordingly, based on evidence from all identifiable trials we are 39 40 unable to recommend or refute methylphendiate for the treatment of ADHD in children and 41 42 adolescents. 43 44 45 Word count: 374. 46 47 48 49 50 51 52 53 54 55 56 4 57 58 59 60 https://mc.manuscriptcentral.com/bmj Page 5 of 615 BMJ 1 2 3 4 5 6 7 8 Confidential: For Review Only 9 10 11 12 Introduction 13 14 Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and 15 1 2 16 treated childhood psychiatric disorders with a prevalence of 3% to 5%, depending on the 17 18 classification system used. ADHD is increasingly seen as a developmental disorder, which has high 19 comorbidity with other psychiatric disorders.3 Diagnosis is made through recognition of excessive 20 21 inattention, hyperactivity and impulsivity in a child, before 12 years of age, that impairs his or her 22 23 functioning or development.4 5 24 25 26 27 Methylphenidate has been used for the treatment of ADHD for over 50 years and is now globally 28 29 the most common treatment for ADHD. 6 7 Despite the widespread use of methylphenidate there has 30 31 not been a comprehensive systematic review of both benefits and harms. Fifteen reviews of the 32 33 effect of methylphenidate on the symptoms of ADHD in children and adolescents have been 34 8-22 35 published. None of them were conducted using Cochrane methodology and none pre-published a 36 peer-reviewed protocol. Twelve did not undertake subgroup analyses regarding comorbidity 37 38 influencing treatment 9-11 13-19 22 nor did they control for the effect of ADHD subtypes on treatment. 8- 39 40 11 15-22 Twelve did not consider dosage 8 9 11-14 16-20 22 and four did not undertake meta-analyses.9 10 41 42 14 16 Seven meta-analyses combined outcome data across raters and observers 8-10 15-17 20 and nine did 43 44 not separate outcomes for inattention and hyperactivity/impulsivity.
Load more

Recommended publications
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • AO-Klasifikácia Faktúr →Zlomeniny
    AO-klasifikácia faktúr →zlomeniny. AOP-syndróm – skr. syndroma adipositas–oligomenorrhoea–parotis. aorta – [g. aorté srdcovnica] srdcovnica. Začína sa z ľavej komory a vystupuje kraniálne aţ do výšky 2. pravého sternokostálneho kĺbu ako aorta ascendens, pokračovaním je oblúk arcus aortae, aorta descendens, aorta thoracia a aorta abdominalis. Aorta ascendens – začína sa v ľavej komore nad polmesiačikovitými chlopňami a skoro celá sa nachádza v perikarde. Je dlhá asi 4 – 5 cm, jej priemer je 22 – 30 mm. Ihneď nad chlop-ňami je následkom spätných nárazov krvi mierne vydutá do tzv. sinus aortae, výraznejšie u starších osôb. Oddiely a. obsahujúce sinus aortae sa nazývajú bulbus aortae. U starších osôb býva následkom nárazov krvi širší aj koncový úsek vzostupnej a. pred jej prechodom do oblúka, tzv. sinus maximus (quartus) aortae. Tu býva u starších osôb a. často rozširená. A. ascendens, ako aj začiatok arcus aortae majú špeciálne vasa vasorum pochádzajúce z vencovitých tepien (aa. cardiaortales). Tento úsek osobitne patogeneticky rizikový. Začiatok aorta ascendens je ešte obalený vo vagina serosa arteriarum, kt. tvorí na ventrálnom obvode a. priečnu krkvu podloţenú subseróznym tukovým väzivom (Concatova-Bacceli tuková krkva). Vnútri vagina arteriarum je aorta ascendens a začiatrok a. pulmonalis spojené tuhým väzivom (vincula aortae Rindfleischi). Výstup aorta ascendens kryje spredu začiatok a. pulmonalis, ventrálne a vpravo je auricula dextra, dorzálne je uloţený r. dexter a. pulmonalis. Kraniálne vpravo od a. je v. cava superior, vľavo kmeň a. pulmonalis. Z ventrálneho a ľavého sinus aortae sa začína a. coronaria cordis dextra et sinistra. Aorta ascendens a arcus aortae Arcus aortae – je dlhý asi 6 cm, začína sa za sternom vo výške úponu 2.
    [Show full text]
  • Medical Review Officer Manual
    Department of Health and Human Services Substance Abuse and Mental Health Services Administration Center for Substance Abuse Prevention Medical Review Officer Manual for Federal Agency Workplace Drug Testing Programs EFFECTIVE OCTOBER 1, 2010 Note: This manual applies to Federal agency drug testing programs that come under Executive Order 12564 dated September 15, 1986, section 503 of Public Law 100-71, 5 U.S.C. section 7301 note dated July 11, 1987, and the Department of Health and Human Services Mandatory Guidelines for Federal Workplace Drug Testing Programs (73 FR 71858) dated November 25, 2008 (effective October 1, 2010). This manual does not apply to specimens submitted for testing under U.S. Department of Transportation (DOT) Procedures for Transportation Workplace Drug and Alcohol Testing Programs (49 CFR Part 40). The current version of this manual and other information including MRO Case Studies are available on the Drug Testing page under Medical Review Officer (MRO) Resources on the SAMHSA website: http://www.workplace.samhsa.gov Previous Versions of this Manual are Obsolete 3 Table of Contents Chapter 1. The Medical Review Officer (MRO)........................................................................... 6 Chapter 2. The Federal Drug Testing Custody and Control Form ................................................ 7 Chapter 3. Urine Drug Testing ...................................................................................................... 9 A. Federal Workplace Drug Testing Overview..................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • UFC PROHIBITED LIST Effective June 1, 2021 the UFC PROHIBITED LIST
    UFC PROHIBITED LIST Effective June 1, 2021 THE UFC PROHIBITED LIST UFC PROHIBITED LIST Effective June 1, 2021 PART 1. Except as provided otherwise in PART 2 below, the UFC Prohibited List shall incorporate the most current Prohibited List published by WADA, as well as any WADA Technical Documents establishing decision limits or reporting levels, and, unless otherwise modified by the UFC Prohibited List or the UFC Anti-Doping Policy, Prohibited Substances, Prohibited Methods, Specified or Non-Specified Substances and Specified or Non-Specified Methods shall be as identified as such on the WADA Prohibited List or WADA Technical Documents. PART 2. Notwithstanding the WADA Prohibited List and any otherwise applicable WADA Technical Documents, the following modifications shall be in full force and effect: 1. Decision Concentration Levels. Adverse Analytical Findings reported at a concentration below the following Decision Concentration Levels shall be managed by USADA as Atypical Findings. • Cannabinoids: natural or synthetic delta-9-tetrahydrocannabinol (THC) or Cannabimimetics (e.g., “Spice,” JWH-018, JWH-073, HU-210): any level • Clomiphene: 0.1 ng/mL1 • Dehydrochloromethyltestosterone (DHCMT) long-term metabolite (M3): 0.1 ng/mL • Selective Androgen Receptor Modulators (SARMs): 0.1 ng/mL2 • GW-1516 (GW-501516) metabolites: 0.1 ng/mL • Epitrenbolone (Trenbolone metabolite): 0.2 ng/mL 2. SARMs/GW-1516: Adverse Analytical Findings reported at a concentration at or above the applicable Decision Concentration Level but under 1 ng/mL shall be managed by USADA as Specified Substances. 3. Higenamine: Higenamine shall be a Prohibited Substance under the UFC Anti-Doping Policy only In-Competition (and not Out-of- Competition).
    [Show full text]
  • Functional Characterization of the Dopaminergic Psychostimulant Sydnocarb As an Allosteric Modulator of the Human Dopamine Transporter
    biomedicines Article Functional Characterization of the Dopaminergic Psychostimulant Sydnocarb as an Allosteric Modulator of the Human Dopamine Transporter Shaili Aggarwal 1, Mary Hongying Cheng 2 , Joseph M. Salvino 3 , Ivet Bahar 2 and Ole Valente Mortensen 1,* 1 Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA; [email protected] 2 Department of Computational and Systems Biology, School of Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA; [email protected] (M.H.C.); [email protected] (I.B.) 3 The Wistar Institute, Philadelphia, PA 19104, USA; [email protected] * Correspondence: [email protected] Abstract: The dopamine transporter (DAT) serves a critical role in controlling dopamine (DA)- mediated neurotransmission by regulating the clearance of DA from the synapse and extrasynaptic regions and thereby modulating DA action at postsynaptic DA receptors. Major drugs of abuse such as amphetamine and cocaine interact with DATs to alter their actions resulting in an enhancement in extracellular DA concentrations. We previously identified a novel allosteric site in the DAT and the related human serotonin transporter that lies outside the central orthosteric substrate- and cocaine-binding pocket. Here, we demonstrate that the dopaminergic psychostimulant sydnocarb is a ligand of this novel allosteric site. We identified the molecular determinants of the interaction between sydnocarb and DAT at the allosteric site using molecular dynamics simulations. Biochemical- Citation: Aggarwal, S.; Cheng, M.H.; Salvino, J.M.; Bahar, I.; Mortensen, substituted cysteine scanning accessibility experiments have supported the computational predictions O.V. Functional Characterization of by demonstrating the occurrence of specific interactions between sydnocarb and amino acids within the Dopaminergic Psychostimulant the allosteric site.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Terminoloogia Raamat.Pdf
    A I G O O L O N I M R E T A I S T A A M R A F FARMAATSIATERMINOLOOGIA Euroopa farmakopöa ravimvormid, manustamisviisid, pakendid ja droogid ATC süsteemid FARMAATSIATERMINOLOOGIA Euroopa farmakopöa ravimvormid, manustamisviisid, pakendid ja droogid ATC süsteemid Tartu 2010 Koostajad: Toivo Hinrikus, Mailis Jaamaste, Eveli Kikas, Peet-Henn Kingisepp, Ott Laius, Ain Raal, Sander Sepp, Ave-Ly Toomvap, Peep Veski, Daisy Volmer Farmaatsiaterminoloogia ekspertkomisjoni liikmed aastast 1999 (Tartu Ülikool): Toivo Hinrikus, Peet-Henn Kingisepp, Ain Raal, Peep Veski, Daisy Volmer Farmaatsiaterminoloogia ekspertkomisjoni liikmed aastatel 1999–2009 (Ravimiamet): Birgit Aasmäe, Malle Jaagola, Mailis Jaamaste, Eveli Kikas, Silja Kokk, Signe Leito, Margit Plakso, Lembit Rägo, Helga Suija, Ave-Ly Toomvap, Merje Veeberg Keeletoimetaja: Rutt Läänemets Kaanefoto: Ain Raal Kirjastanud: Ravimiamet Nooruse 1, 50411 Tartu Telefon: +372 737 4140 Faks: +372 737 4142 E-post: [email protected] Trükise väljaandmist toetasid Eesti Terminoloogia Ühing ja Haridus- ja Teadusministeerium projekti „Terminikomisjonide toetuskonkurss 2009“ raames. Väljaande refereerimisel või tsiteerimisel palume viidata allikale. ISBN 978-9949-18-919-9 Saateks Räägime ravimitest eesti keeles Ravimimaailmas toimub üleilmastumine tohutu hooga. Sageli mõeldakse ravim välja ühes, selle omadusi ja toimet hinnatakse teises ning seda toodetakse kolmandas maailma nurgas. Sama ravimit võivad kasutada arstid, apteekrid ja patsiendid üle kogu maailma. Kui ravimi kõrvaltoime registreeritakse näiteks Portugalis, peame meiegi Eestis sellest oma järel- dused tegema ja teadma, mis on sellest oluline meie patsientide jaoks. Selleks, et ravimitega tegelejad erinevates riikides üksteist mõistaksid, peavad nad kasutama ühtset terminoloogiat. Nüüdisajal on üldkasutatavaks suhtlemisvahendiks teatavasti inglise keel. Just inglise keeles trükitud Euroopa farmakopöa on aluseks ravimitega seonduvate terminite kasuta- misele kogu Euroopas.
    [Show full text]
  • Doping Control of Athletes
    trends in analytical chemistry, vol. 7, no. IO, I988 375 trends Doping control of athletes E. G. de Jong*, I?. A. A. Maes and The definition of the Council of Europe for doping J. M. van Rossum is2: Utrecht, Netherlands ‘The administration to or the use by a healthy indi- vidual in any way of compounds which are not natu- History ral to the organism or the use of physiological com- The origin of the word doping is not certain. It first pounds in abnormal doses or in an abnormal way appeared in the English dictionaries at the end of the with the only purpose to artificially and dishonestly nineteenth century. The first reference to the use of influence the performance of this person during doping by athletes was in 1864 during swimming competition.’ competitions that were held in the canals of Amster- Another possible definition is: dam. The use of what is known as a ‘speedball’, a ‘The use of compounds which are not synthesized mixture of heroine and cocaine, by cyclists was de- by the human body or the use of endogenous com- scribed in 1869. In 1904 the Russian chemist pounds in excessive doses with the aim to improve Bukowski was able to identify some alkaloids in the performance in sport competitions.’ saliva of horses’. A simpler definition is: Australia was the first country to take measures ‘The use of forbidden drugs. ’ against doping in sports in 1962, and England fol- The last definition can only be used when we have lowed with the drugs bill in 1964.
    [Show full text]
  • NIDA Drug Supply Program Catalog, 25Th Edition
    RESEARCH RESOURCES DRUG SUPPLY PROGRAM CATALOG 25TH EDITION MAY 2016 CHEMISTRY AND PHARMACEUTICS BRANCH DIVISION OF THERAPEUTICS AND MEDICAL CONSEQUENCES NATIONAL INSTITUTE ON DRUG ABUSE NATIONAL INSTITUTES OF HEALTH DEPARTMENT OF HEALTH AND HUMAN SERVICES 6001 EXECUTIVE BOULEVARD ROCKVILLE, MARYLAND 20852 160524 On the cover: CPK rendering of nalfurafine. TABLE OF CONTENTS A. Introduction ................................................................................................1 B. NIDA Drug Supply Program (DSP) Ordering Guidelines ..........................3 C. Drug Request Checklist .............................................................................8 D. Sample DEA Order Form 222 ....................................................................9 E. Supply & Analysis of Standard Solutions of Δ9-THC ..............................10 F. Alternate Sources for Peptides ...............................................................11 G. Instructions for Analytical Services .........................................................12 H. X-Ray Diffraction Analysis of Compounds .............................................13 I. Nicotine Research Cigarettes Drug Supply Program .............................16 J. Ordering Guidelines for Nicotine Research Cigarettes (NRCs)..............18 K. Ordering Guidelines for Marijuana and Marijuana Cigarettes ................21 L. Important Addresses, Telephone & Fax Numbers ..................................24 M. Available Drugs, Compounds, and Dosage Forms ..............................25
    [Show full text]